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Abstract
Introduction: Levosimendan is an extensively investigated inodilator showing also cardioprotective and
antiinflammatory effects. The aim of our study was to explore the influence of levosimendan on
polymorphonuclear leucocytes (PMN), a main source of reactive oxygen species, in vitro and in patients with acute
heart failure or septic myocardial depression.
Methods: PMN isolated from healthy volunteers were incubated with levosimendan in vitro. After stimulation with
N-formyl-Met-Leu-Phe (fMLP) or phorbol 12-myristate 13-acetate (PMA) respiratory burst was quantified using a
fluorescent dye. Apoptosis and expression of cell adhesion molecules of PMN were measured by flow cytometry.
For determination of in vivo effects patients with acute heart failure (n = 16) or septic cardiac failure (n = 9)
receiving levosimendan treatment were enrolled consecutively. PMN were isolated to measure respiratory burst
activity before treatment as well as one and two hours after initiation of levosimendan administration. Furthermore
inflammatory, hemodynamic and renal function parameters were obtained.
Results: In vitro, levosimendan suppressed respiratory burst activity in fMLP or PMA stimulated PMN in a dose
dependent manner by 30 ± 11% (P < 0.001) at 100 ng/mL and by 27 ± 17% (P < 0.001) at 1000 ng/mL
respectively. Markers of apoptosis and PMN cell adhesion molecule expression remained unaffected by
levosimendan treatment.
In vivo, levosimendan treatment for two hours resulted in a significant reduction of PMA stimulated oxidative burst
by 45% (P < 0.01) and fMLP stimulated oxidative burst by 49% (P < 0.05) in patients with acute heart failure. In
patients suffering from septic shock levosimendan treatment decreased oxidative burst activity in unstimulated,
fMLP and PMA stimulated PMN by 48% (P < 0.05), 46% (P < 0.01) and 43% (P < 0.01) respectively.
Conclusions: Levosimendan appears to exert distinct immunomodulatory effects by decreasing oxidative burst
activity of PMN. This property might contribute to the previously described cardioprotective effects of the drug.
Introduction
Recent evidence extended the classic paradigm of acute
heart failure as an exclusive problem of low cardiac out-
put to a syndrome comprising exaggerated inflammatory
response. This reaction is characterized by complement
activation, release of cytokines and production of other
inflammatory mediators, which may play a crucial role
in the pathogenesis and prognosis of cardiogenic shock
[1-3]. Polymorphonuclear leukocytes (PMN) are thought
to play a key role in this process by producing myelo-
peroxidase, which has been shown to be a biomarker of
inflammation and oxidative stress as well as an indepen-
dent predictor of one-year mortality in acute heart fail-
ure [4]. Myeloperoxidase is an essential enzyme for the
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involved in many biological processes contributing to
the development and progression of heart failure [5].
ROS lead to oxidative damage, cardiomyocyte apoptosis,
direct negative inotropic effects and reduced bioavail-
ability of nitric oxide [6,7].
In severe sepsis and septic shock, enhanced neutrophil
activation is reflected by higher oxidative burst activity
and is associated with increased mortality [8]. Myocar-
dial depression is a frequently recognized manifestation
of organ dysfunction in sepsis and can be attributed to
several underlying mechanisms, such as endotoxinemia
and overwhelming production of cytokines, nitric oxide
or ROS, as well as decreased myofibrillar sensitivity to
calcium [9-11].
Levosimendan is a Ca
2+ sensitizer and inodilator,
which has been used successfully in the management of
acute heart failure [12]. Additionally, its immunomodu-
latory and antiapoptotic properties may provide distinct
biologic mechanisms that prevent further cytotoxic and
hemodynamic consequences of abnormal immune and
neurohumoral responses in acute heart failure [13-16].
Experimental data show that levosimendan exerts a pro-
tective action by its antioxidant properties and inhibits
hydrogen peroxide (H2O2)-induced apoptotic cell death
in cardiomyocytes [17].
Several studies have also addressed the use of levosi-
mendan as a potent inotropic substance in sepsis and
septic shock [18-20] showing beneficial effects on sys-
temic hemodynamics and regional perfusion [21] as well
as microcirculatory blood flow [22]. A recent study
focused on the beneficial combination of levosimendan
and glibenclamide in septic shock, where levosimendan
was supposed to antagonize cardiodepression and glib-
enclamide to inhibit sepsis-induced vasodilatory effects
[23]. Despite increasing evidence to extend the indica-
tion of levosimendan to sepsis-induced myocardial
depression in critically ill patients there is still a lack of
knowledge about its exact mechanisms of action in this
specific clinical setting [24].
The aim of the present study was to investigate anti-
inflammatory and antioxidative properties of levosi-
mendan by determining its effect in human PMN. For
this purpose we examined the in vitro effects of levosi-
mendan on the release of ROS, surface expression of
adhesion molecules as well as apoptosis in PMN iso-
lated from healthy volunteers. Additionally, we con-
ducted an observational study in critically ill patients
treated with levosimendan for acute heart failure or
septic shock with sepsis-associated myocardial depres-
sion exploring direct drug effects of levosimendan on
respiratory burst activity ofP M Ni s o l a t e df r o mt h e s e
patients.
Materials and methods
In vitro experiments
Preparation of polymorphonuclear leukocytes
PMN were isolated from EDTA treated blood obtained
from healthy volunteers. The study protocol was
approved by the local Ethics Committee. Written
informed consent was obtained from each volunteer.
Density gradient centrifugation was performed with Bio-
coll separating solution (Biochrom AG, Berlin, Ger-
many) followed by hypotonic lysis of contaminating
erythrocytes. The cell preparation was resuspended in
medium (HBSS (phenol red free, with Ca
2+ and Mg
2+)
GIBCO, Invitrogen, Carlsbad, CA, USA) containing
0.05% BSA (Sigma Aldrich, Munich, Germany).
Levosimendan incubation
PMN (5 × 10
6/mL) were incubated at 37°C (5% CO2
atmosphere) with medium (i.e. control) or various con-
centrations of levosimendan (Simdax™, Abbott, Vienna,
Austria) ranging from 10 to 1000 ng/mL and then
brought to a final volume of 200 μl/well (96-well plate)
containing 10 μM2 ’,7’dichlorodihydrofluoresceindiace-
tate (H2DCFDA; Invitrogen, Carlsbad, CA, USA) in
HBSS. Concentrations were chosen from 10 to 1000 ng/
mL to cover therapeutical plasma concentrations usually
observed after intravenous administration of levosimen-
dan. An infusion rate of 0.1 μg/kg/min was reported to
result in a plasma concentration of 35 ± 9 ng/mL at
steady state [25]. Time course experiments applying dif-
ferent incubation periods from 30 minutes to 2 hours
have revealed a maximum effect already after 30 min-
utes. Therefore, this incubation period for levosimendan
was chosen for all further experiments.
Determination of basal and stimulated oxidative burst
activity of PMN
PMN were placed in a humified incubator (37°C, 5%
CO2) for various time intervals with medium (basal
activity) or the triggering agents (stimulated activity): 1
μM N-formyl-Met-Leu-Phe (fMLP; Sigma Aldrich,
Munich, Germany) or 324 nM phorbol 12-myristate 13-
acetate (PMA; Sigma Aldrich, Munich, Germany).
Respiratory burst activity was measured using
H2DCFDA as a fluorochrome. The assay is based on the
oxidation of non-fluorescent H2DCFDA to highly fluor-
escent 2’-7’ dichlorofluorescein (DCF), both intracellu-
larly and extracellularly. Fluorescent activity was
determined at 485 ± 20 nm excitation and 530 ± 25 nm
emission wavelengths using a multiwell plate reader
(Cytofluor 2350 fluorescence measurement system,
Millipore Corp., Billerica, MA, USA).
Scavenging of reactive oxygen species
To determine the ability of levosimendan to directly sca-
venge ROS, hydrogen superoxide (10 μmol/L) was used
at room temperature either in medium or in presence of
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mL) to create ROS. Generation of ROS was quantified
by measuring fluorescence activity of DCF as described
above. To exclude effects of autofluorescence experi-
ments were repeated without hydrogen superoxide.
Apoptosis of PMN
PMN were preincubated for 30 minutes with levosimen-
dan (10 to 1000 ng/mL) at 37°C in humidified atmo-
sphere and then incubated with medium (i.e. control) or
human TNFa (1 ng/mL and 10 ng/mL) for additional
four hours. Early apoptosis of PMN was assessed using
the human Annexin V-FITC-kit (BenderMedSystems,
Vienna, Austria) following the manufacturer’si n s t r u c -
tions. Fluorescence activated cell sorting (FACS) analysis
was performed using a FACSCalibur (BD Biosciences,
San Jose, CA, USA). Numbers of apoptotic PMN were
calculated as the percentage of gated cells showing posi-
tive staining for Annexin V but no uptake of propidium
iodide. PMN with uptake of propidium iodide were con-
sidered as necrotic cells.
Surface expression of CD62L (selectin) and CD18 (integrin)
on PMN
PMN (10
6/mL) were incubated at 37°C with medium
(control) or various concentrations of levosimendan (10
to 1000 ng/mL) for 30 minutes. For FACS analyses of
cell adhesion molecule expression, freshly prepared
PMN were washed twice and stained with monoclonal
antibodies (FITC mouse anti-human CD18 or FITC
mouse anti-human CD62L) or an isotype control anti-
body (FITC mouse IgG1k) and kept on ice in the dark
for 20 minutes in PBS supplemented with 5% FCS. After
additional washing steps, cells were resuspended in PBS
and analyzed on a FACSCalibur. All antibodies were
purchased from BD Pharmingen (BD Biosciences, San
Diego, CA, USA).
Patient study
Patients
Consecutive patients treated with levosimendan were
enrolled at the medical ICU of the University Hospital
of Innsbruck from January 2008 to January 2010. They
were eligible for inclusion if they received levosimendan
as intravenous inotropic therapy due to the following
criteria:
A) Patients with acute heart failure received levosi-
mendan if they fulfilled at least three of the following
six criteria: 1) neurohumeral therapy (diuretics, b-block-
ers, calcium antagonists, angiotensin-converting enzyme
inhibitors, sartans); 2) a history of progredient dyspnea
since three days before admission; 3) radiologic signs of
pulmonary fluid overload; 4) deterioration of a known
chronic heart failure (ejection fraction (EF) <35%); 5)
myocardial stunning due to myocardial infarction or
mechanical C-reactive protein (CPR); 6) low-output
heart failure (EF <35% determined by transthoracic
echocardiography).
B) Patients with septic shock (defined according to the
criteria of the International Sepsis Definition Conference
[26]) suffering from septic cardiac failure were included
if they fulfilled the following criteria: 1) at least two of
four systemic inflammatory response syndrome (SIRS)
criteria; 2) documented or suspected infection; 3) vaso-
pressor support; 4) septic myocardial depression defined
as worsening heart failure in the course of sepsis with
an EF less than 45% [21].
Preload optimization by fluid administration and/or
vasopressor treatment aiming at a mean arterial pressure
(MAP) of 65 mmHg or higher were performed in all
patients before being considered for levosimendan
treatment.
Protocol
Levosimendan was infused continuously for 24 hours.
Infusion was started at 0.10 μg/kg/min and titrated up
to a maximum of 0.15 μg/kg/min, if hemodynamically
tolerated, until a cumulative dose of 12.5 mg was
reached. Blood samples for oxidative burst measure-
ments were drawn before, one hour and two hours after
the start of levosimendan treatment. Preparation of
PMN and determination of basal and stimulated respira-
tory burst activity were performed according to the pro-
tocol described above.
Inflammatory markers (leukocyte counts, CRP, procal-
citonin, and serum IL-6) as well as renal function para-
meters (serum creatinine, serum urea, and serum
cystatin C) were determined just before the start and at
the end of the levosimendan infusion (± four hours).
Serum IL-6 levels were measured with an ELISA kit
according to the manufacturer’s specifications (BD
OptiEIA™, Human IL-6 ELISA set, BD Biosciences, San
Diego, CA, USA).
Hemodynamic parameters were assessed before and
after levosimendan therapy using either transthoracical
echocardiography (EF), minimal invasive monitoring (Vigi-
leo, Edwards Life Sciences, Irvine, CA, USA; PICCO2,P u l -
sion Medical Systems AG, Munich, Germany), or a
pulmonary artery catheter (Edwards Life Sciences, Irvine,
CA, USA). Sequential Organ Failure Assessment score
(SOFA) and Acute Physiology And Chronic Health Eva-
luation (APACHE) II score, catecholamine therapy, con-
tinuous renal replacement therapy and ventilatory support
were assessed at the day of therapy. ICU survival was
recorded for each group. The study protocol was approved
by the local Ethics Committee. Written informed consent
was obtained from each patient.
Statistics
In vitro data were reported as mean ± standard devia-
tion after verifying normal distribution by the
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dative burst were analyzed with the repeated - measures
analysis of variance followed by Bonferroni post test. In
vivo data were reported as median and interquartile
range. Oxidative burst measurements of patients were
compared by the Friedman test followed by Dunn’s mul-
tiple comparison test. Laboratory and hemodynamic
parameters before and after levosimendan treatment
were compared with the Mann Whitney U test. Values
of P less than 0.05 were considered as statistically signif-
icant. SPSS software (PASW statistics 18, SPPS Inc.,
Chicago, Illinois, USA) was used to analyze data.
Results
In vitro experiments
Effect of levosimendan on oxidative burst activity of PMN
Incubation with levosimendan resulted in a dose-depen-
dent reduction of oxidative burst reaching statistical sig-
nificance at 50, 100 and 1000 ng/mL in fMLP-
stimulated PMN and at 100 and 1000 ng/mL in PMA-
stimulated PMN (Figure 1). A similar trend was found
in unstimulated PMN, which, however, was not statisti-
cally significant. The maximum effect was seen at 100
ng/mL in fMLP-stimulated PMN showing a reduction of
30 ± 11% (P < 0.001) and at 1000 ng/mL in PMA-sti-
mulated PMN showing a reduction of 27 ± 17% (P <
0.001). Additional control experiments demonstrated
that levosimendan is not able to scavenge free oxygen
radicals (Figure 2).
Effects of levosimendan on apoptosis of PMN
In healthy volunteers, 4.2 ± 1.7% of untreated PMN
were annexin positive (control in Figure 3a). Exposure
of PMN to TNFa (10 ng/mL) significantly increased
apoptosis to 10.9 ± 3.0% (P < 0.01; control in Figure
3b). The rate of necrotic cells did not exceed 1% in
untreated and 3% in TNFa-treated cells. Incubation of
PMN with levosimendan did not influence the percen-
tage of apototic cells at any concentration (10 to 100
ng/mL; Figure 3a). Preincubation with levosimendan
prior to TNFa (10 ng/mL) exposure had no effect on
apoptosis induced by TNFa (Figure 3b).
Expression of selectins (CD62L) and integrins (CD18) on the
surface of PMN
Significant surface expression of integrins (Figure 4a)
and selectins (Figure 4b) could be detected in
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Figure 1 In vitro effects of levosimendan on oxidative burst. Oxidative burst of (a) unstimulated, (b) N-formyl-Met-Leu-Phe (fMLP) and (c)
phorbol 12-myristate 13-acetate (PMA) stimulated polymorphonuclear leukocytes (PMN); PMN were incubated with various concentrations of
levosimendan ranging from 10 to 1000 ng/mL or control (PMN without levosimendan treatment); Graph shows mean ± standard deviation; n =
11; RFU, relative fluorescence units; ** P < 0.01, *** P < 0.001.
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Figure 2 Scavenging capability of levosimendan. Oxidation of
2’,7’dichlorodihydrofluoresceindiacetate (H2DCFDA) to fluorescent 2’-
7’ dichlorofluorescein (DCF) reflected by fluorescent activity (RFU)
was measured in the presence of medium (i.e. control) or various
concentrations of levosimendan (10 to 1000 ng/mL) with or without
addition of hydrogen peroxide (H2O2). A scavenging activity of
levosimendan would result in a reduction of RFU compared with
control. The experiment without hydrogen peroxide was performed
to exclude possible autofluorescence of levosimendan. Data are
expressed as mean ± standard deviation. RFU, relative fluorescence
units.
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dan (10 ng/mL to 1000 ng/mL) for 30 minutes did not
show a significant effect on surface expression of
CD62L and CD18.
Patient study
Study population
The study population consisted of 25 consecutive
patients including 16 patients with acute heart failure
and 9 patients with septic shock showing septic myocar-
dial depression. The demographic data of each group is
shown in Table 1, and hemodynamic and laboratory
parameters are shown in Tables 2 and 3.
Hemodynamic parameters
Patients with acute heart failure showed a significant
increase in EF from 24% (20 to 29%) to 38% (29 to 59%;
P = 0.003) and cardiac index from 2.5 l/min/m
2 (2.3 to
2.6 l/min/m
2) to 2.7 l/min/m
2 (2.6 to 3.3 l/min/m
2; P =
0.04) following levosimendan infusion, whereas
hemodynamic parameters in patients with septic shock
remained unchanged (Table 2).
Vasopressor support
During levosimendan therapy, 7 of 16 patients with
acute heart failure required vasopressor support as fol-
lows: six received noradrenaline infusion with a dose of
0.26 μg/kg/min (0.12 to 0.40 μg/kg/min) at baseline,
0.24 μg/kg/min (0.08 to 0.36 μg / k g / m i n )a to n eh o u r ,
and 0.24 μg/kg/min (0.07 to 0.33 μg / k g / m i n )a tt w o
hours of levosimendan treatment. Two patients received
dobutamine prior to levosimendan with an average dose
of 2.4 μg/kg/min.
In contrast, all patients with septic shock required
vasopressor support. Before levosimendan therapy the
average dose of noradrenaline administered was 0.27 μg/
kg/min (0.23 to 0.39 μg/kg/min), after one hour 0.25 μg/
kg/min (0.20 to 0.36 μg/kg/min), and after two hours
0.25 μg/kg/min (0.22 to 0.35 μg/kg/min). Two patients
received dobutamine before levosimendan therapy with
an average dose of 7.5 μg/kg/min.
ICU survival
No differences could be observed in respiratory burst
activity, decrease of respiratory burst activity within two
hours, or serum IL-6 levels between survivors and non-
survivors in patients with acute heart failure or septic
shock.
Respiratory burst activity of patients treated with
levosimendan
Patients with acute heart failure (n = 16) There was a
significant reduction of oxidative burst from baseline
(100%) by 28% (15 to 45%) after one hour (P < 0.05)
and by 45% (10 to 73%; P < 0.01) after two hours of
levosimendan infusion in PMA-stimulated PMN and a
significant reduction by 49% (-15 to 74%; P < 0.05) after
two hours in fMLP-stimulated PMN. No significant
change was observed in unstimulated cells (Figure 5).
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Figure 3 Apoptosis of PMN incubated with levosimendan.
Graphs show the percentage of annexin positive, propidium iodide
positive as well as double positive (annexin and propidium iodide)
cells; Data are expressed as mean ± standard deviation; n = 5. (a)
Polymorphonuclear leukocytes (PMN) were incubated with medium
(control) or various concentrations of levosimendan (10 to 1000 ng/
mL). (b) PMN were preincubated with medium (control) or various
concentrations of levosimendan (10 to 1000 ng/mL) and then
exposed to TNFa (10 ng/mL).
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Figure 4 Expression of cell adhesion molecules. Surface antigen
expression of polymorphonuclear leukocytes (PMN) after incubation
with various concentrations of levosimendan (10 to 1000 ng/mL) or
medium (i.e. control). (a) CD18 (integrin) and (b) CD62L (selectin);
data are expressed as mean ± standard deviation; n = 4; MCV,
mean channel value.
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tic patients levosimendan did reduce respiratory burst
within two hours by 48% (38 to 65%) in unstimulated
PMN (P < 0.05), by 46% (32 to 64%) in fMLP-stimulated
PMN (P < 0.01) and 43% (24 to 53%) in PMA-stimu-
lated PMN (P < 0.01; Figure 5).
Discussion
Effects of levosimendan on reactive species production of
PMN
The present study demonstrates for the first time that
levosimendan significantly suppresses ROS production
of human PMN isolated from healthy volunteers. This
in vitro effect could be reproduced in critically ill
patients with acute heart failure as well as in patients
with septic cardiac failure receiving levosimendan. A sig-
nificant reduction of respiratory burst was already
observed one hour after the start of levosimendan treat-
ment but became even more pronounced after two
hours of treatment. In patients with septic shock, oxida-
tive burst activity was reduced in unstimulated as well
as in stimulated PMN whereas in patients with acute
heart failure only stimulated oxidative burst was
suppressed by levosimendan. These findings may indi-
cate a different inflammatory state in the presence of
sepsis, where levosimendan does not only reduce stimu-
lated but also basal rates of respiratory burst by about
40 to 50%. Generally higher oxidative burst activities of
unstimulated PMN could be observed in critically
patients as compared with healthy volunteers.
Based on the time-dependent effect of levosimendan
within two hours, we assume a direct mechanism of
action responsible for the observed influence on PMN
rather than clinical improvement, which usually is not
observed within such a short time span. Accordingly,
inflammatory markers like leukocyte count, CRP, procal-
citonin, and serum IL-6 levels did not change signifi-
cantly over 24 hours in patients treated with
levosimendan. This hypothesis is further substantiated
by the results of our in vitro experiments where only 30
minutes of levosimendan incubation of PMN isolated
from healthy volunteers was sufficient to induce a signif-
icant reduction of respiratory burst activity.
Above all, our results support previous findings in
patients with advanced heart failure showing that levosi-
mendan does not increase circulating markers of
Table 1 Patient characteristics
Acute heart failure (n = 16) Septic cardiac failure (n = 9)
Mean age 69 (17) 74 (16)
Women 4 (25%) 2 (22%)
SOFA Score 6 (5-10) 13 (11-16)
APACHE II Score 16 (11-19) 20 (15-27)
Patients on catecholamines 7 (44%) 9 (100%)
Patients on mechanical ventilation 7 (44%) 9 (100%)
Patients on CRRT 4 (25%) 8 (89%)
ICU Survival 12 (75%) 2 (22%)
Table shows demographic data of patients with acute heart failure or septic cardiac failure; Age, Sequential Organ Failure Assessment (SOFA) score and Acute
Physiology And Chronic Health Evaluation (APACHE) II score are expressed as median (interquartile range); the other parameters are expressed in numbers (%);
CRRT, continuous renal replacement therapy.
Table 2 Hemodynamic parameters of patients treated with levosimendan
A) Acute heart failure (n = 16)
Hemodynamic parameters before levosimendan after levosimendan P value
EF (%) 24 (20-29) 38 (29-59) 0.003
MAP (mmHg) 80 (70-90) 75 (70-80) ns
CVP (mmHg) 8 (6-15) 9 (5-14) ns
CI (l/min/m
2) 2.5 (2.3-2.6) 2.7 (2.6-3.3) 0.04
B) Septic cardiac failure (n = 9)
Hemodynamic parameters before levosimendan after levosimendan P value
EF (%) 29 (21-30) 30 (22-38) ns
MAP (mmHg) 75 (73-80) 75 (75-85) ns
CVP (mmHg) 9 (5-13) 12 (9-14) ns
CI (l/min/m
2) 2.2 (1.9-3.0) 3.2 (2.4-3.9) ns
Table shows hemodynamic parameters of (a) patients with acute heart failure (n = 16) and (b) patients with septic cardiac failure (n = 9) before levosimendan
treatment and after levosimendan treatment (after 24 hours). Data are expressed as median (interquartile range).
CI, cardiac index; CVP, central venous pressure; EF, ejection fraction; MAP, mean arterial pressure; ns, not significant.
Hasslacher et al. Critical Care 2011, 15:R166
http://ccforum.com/content/15/4/R166
Page 6 of 10oxidative and nitrosative stress in contrast to placebo
[27]. Malondialdehyde, as a marker of oxidative stress,
was even significantly reduced by levosimendan com-
pared with dobutamine after five days of treatment [14].
The influence of levosimendan on these markers in
patients with septic shock has not been investigated so
far. Of notice, the antioxidative and antiinflammtory
effects reported cannot be explained by ROS scavenging
activity of the drug itself, which we could exclude by
our in vitro investigation.
Effects of levosimendan on apoptosis and cell adhesion
molecules
Treatment of patients with acute heart failure with levo-
simendan has been reported to decrease circulating
apoptotic markers such as soluble Fas and Fas-ligand
[13]. Low concentrations of levosimendan may also pre-
vent cardiac myocytes from apoptotic cell death
mediated by ROS after the activation of mitochondrial
ATP-sensitive potassium channels [28]. In a mouse
model, levosimendan improved ventricular function and
inhibited cardiomyocyte apoptosis in severe acute
experimental coxsackie virus myocarditis and was dis-
cussed as a therapeutic option in patients with viral
myocarditis [29]. Therefore, we investigated possible
antiapoptotic effects of levosimendan on PMN in vitro.
In our study, levosimendan had no effect on apoptosis
of PMN and could not prevent PMN from TNFa-
induced apoptotic cell death.
Activation of PMN is associated with the cell surface
expression of selectins and integrins. They play a key
role in rolling and adhesion of leukocytes to the
endothelium. L-selectin (CD62L), which is highly
expressed on resting PMN, is shedded upon cell activa-
tion, whereas the expression of integrins (CD18/11b,
CR3, or Mac-1 complex) increases rapidly [30-32]. In
our study, levosimendan had no influence on adhesion
molecule expression of PMN in vitro.
Possible mechanisms of levosimendan responsible for
inhibition of respiratory burst activity of PMN
The mechanism by which levosimendan depresses
respiratory burst remains speculative. The rapidly
detectable effects of levosimendan shortly after the start
of infusion into patients with acute heart failure are
unlikely the result of hemodynamic improvement. As
there was no change in concomitant treatment within
this short time span the effect can be attributed to levo-
simendan alone. As a Ca
2+ sensitizer, levosimendan
should not lead to substantial changes in intracellular
Ca
2+ levels. At higher concentrations, however, levosi-
mendan exhibits phosphodiesterase III inhibitory effects,
leading to an increase in cyclic adenosine monopho-
sphate, thereby possibly promoting catecholamine
effects. Other phosphodiesterase inhibitors such as amri-
none and enoximone have already been shown to
decrease oxidative burst activity in vitro [33]. Further-
more, levosimendan activates Ca
2+-activated, voltage-
sensitive, and ATP-sensitive potassium channels [34-37].
Membrane hyperpolarization in PMN, mediated through
potassium channels, may blunt the oxidative burst
[38,39]. Thus, reasonable explanations for the inhibitory
Table 3 Laboratory parameters of patients treated with levosimendan
A) Acute heart failure (n = 16)
Laboratory parameters before levosimendan after levosimendan P value
Leukocytes (G/L) 10.5 (8.3-14.8) 10.5 (7.4-15.7) ns
CRP (mg/dL) 3.2 (0.6-4.1) 3.1 (1.7-7.4) ns
Procalcitonin (μg/L) 0.3 (0.1-1.4) 0.4 (0.2-0.8) ns
Serum IL - 6 (pg/mL) 51 (34-327) 44 (38-136) ns
Urea (mg/dL) 75 (56-125) 73 (51-150) ns
Creatinine (mg/dL) 1.6 (0.9-2.4) 1.3 (0.8-2.3) ns
Serum cystatin C (mg/L) 1.6 (1.3-2.4) 1.7 (1.3-2.6) ns
B) Septic cardiac failure (n = 9)
Laboratory parameters before levosimendan after start levosimendan P value
Leucocytes (G/L) 10.5 (7.6-16.3) 11.6 (8.2-14.5) ns
CRP (mg/dL) 14.9 (9.0-21.4) 14.2 (5.3-21.5) ns
Procalcitonin (μg/L) 4.8 (1.1-26.9) 2.8 (1.1-21.3) ns
Serum IL-6 (pg/mL) 649 (387-1097) 787 (477-1033) ns
Urea (mg/dL) 76 (47-128) 82 (46-159) ns
Creatinine (mg/dL) 1.4 (0.8-2.5) 1.6 (0.7-2.1) ns
Serum cystatin C (mg/L) 2.3 (2.0-3.1) 2.4 (2.0-3.0) ns
Table shows laboratory parameters of (a) patients with acute heart failure (n = 16) and (b) patients with septic cardiac failure (n = 9) before levosimendan
treatment and after levosimendan treatment (after 24 hours); Data are expressed as median (interquartile range). CRP, C-reactive protein; ns, not significant.
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mendan may be phosphodiesterase III inhibition or
decreased ROS production caused by activation of
potassium channels.
Clinical impact
Levosimendan treatment resulted in hemodynamic
improvement in patients with acute heart failure [40],
which appeared more effective as compared with dobu-
tamine in previous studies [41]. We did also observe a
significant increase in EF and cardiac index after 24
hours of levosimendan treatment in patients with acute
heart failure. Separate analys i so fp a t i e n t sw i t hs e p t i c
shock showed a similar tendency but did not reach sta-
tistical significance. Beneficial effects of levosimendan in
septic myocardial depression resulting in an increase in
left ventricular EF and cardiac index were reported by
Morelli et al. [21].
One explanation for the improvement of cardiac per-
formance may be the reduction of ROS activity from
PMN thereby protecting cardiomyocytes from the toxic
effects of oxidative stress in addition to its well
described mechanism as an inotropic drug [28]. Unfor-
tunately, we could not observe any relation between a
decrease in oxidative burst and survival. Further studies
are required to demonstrate whether the favorable
hemodynamic effects of levosimendan, as also demon-
strated in the present study, are clearly potentiated by
its anti-inflammatory action.
Limitations
Our study has several limitations. First of all the patient
study was designed as a prospective observational study
with a relatively small number of patients but lacking a
control group. Therefore, we cannot absolutely exclude
that the in vivo effects on respiratory burst observed
may occur from some other factors than levosimendan.
However, by keeping all interventions constant over the
two-hour observation period, we tried to minimize this
possibility. Secondly, blood concentrations of levosimen-
dan in patients were not measured. However, we used
body weight adjusted dosages as recommended by the
manufacturer and the early onset of the effect as well as
the dose-response relation of respiratory burst inhibition
in vitro are indicators of a direct drug effect. Although
the present study does not allow for firm conclusions to
be drawn about the exact mechanism of the inhibition
of respiratory burst, scavenging of free oxygen radicals
or an apoptotic effect on PMN could be clearly
excluded.
Conclusions
It could be demonstrated for the first time that levosi-
mendan reduces oxidative burst activity of PMN both in
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Figure 5 Oxidative burst activity in patients with acute heart
failure or septic shock treated with levosimendan. Basal
oxidative burst and oxidative burst after one hour and two hours of
levosimendan infusion in (a) unstimulated, (b) N-formyl-Met-Leu-
Phe (fMLP) and (c) phorbol 12-myristate 13-acetate (PMA)
stimulated polymorphonuclear leukocytes (PMN) in patients with
septic cardiac failure (n = 9) and patients with acute heart failure (n
= 16); Graph shows box plots (median and inter quartile range);
RFU, relative fluorescence units; * P < 0.05, ** P < 0.01.
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Page 8 of 10vitro and in patients with acute heart failure or septic
shock with septic myocardial depression. This may con-
tribute to the anticipated cardioprotective effects of the
drug.
Key messages
￿ Levosimendan significantly reduces oxidative burst
activity of PMN from healthy volunteers.
￿ Immunomodulation (reduced PMN burst activity)
by levosimendan can also be observed in critically ill
patients suffering from septic shock with septic myo-
cardial depression or acute heart failure.
￿ Levosimendan as a substance does not exhibit free
radical scavenging properties.
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